secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-09-29T23:59:59+00:00
Accession:  0000950170-22-018988
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients
--------------------------------------------------------------------------------

- Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.
- All four fibrosis responders showed stable hemoglobin, WBC, platelets, and spleen volume; no transfusions needed.
- Two patients entered extension phase due to clinical benefit as assessed by treating physician.
- No treatment-related SAEs in the 5-patient evaluable group; one possible SAE (fall) in entire 16-patient trial.
- Company expects top-line results from GULLIVER-2 liver cirrhosis trial in coming weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/0000950170-22-018988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/glto-20220929.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer